GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZS Pharma Inc (FRA:0ZS) » Definitions » Interest Received

ZS Pharma (FRA:0ZS) Interest Received


View and export this data going back to . Start your Free Trial

What is ZS Pharma Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.


ZS Pharma (FRA:0ZS) Business Description

Traded in Other Exchanges
N/A
Address
ZS Pharma Inc was incorporated in Delaware in February 2008. The Company is a biopharmaceutical company engaged in the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It was initially engaged in the development of ZS-9, its product candidate in Phase 3 development for the treatment of hyperkalemia. Hyperkalemia is characterized by elevated levels of potassium in the blood (greater than 5.0 mEq/L) and is a life-threatening condition that occurs frequently in patients with chronic kidney disease (CKD), heart failure, and diabetes. ZS-9 is currently in Phase 3 clinical development. ZS-9 is a therapy to treat hyperkalemia, regardless of the underlying cause, and allows patients to benefit from the cardio-renal protective effect of RAAS therapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that address CKD, HF and metabolic diseases. It faces competition from many pharmaceutical and biotechnology companies that are researching and selling products to treat CKD, HF and metabolic diseases. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.